{"id":5097,"date":"2026-10-08T11:00:02","date_gmt":"2026-10-08T14:00:02","guid":{"rendered":"https:\/\/feadv.com.br\/?p=5097"},"modified":"2026-10-06T11:12:21","modified_gmt":"2026-10-06T14:12:21","slug":"new-regulations-on-oncology-reorganize-access-to-oncological-drugs-in-the-eu-and-may-impact-the-judicialization-of-healthcare","status":"publish","type":"post","link":"https:\/\/feadv.com.br\/en\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/","title":{"rendered":"AF-Onco: new regulations reorganize access to oncological drugs in the SUS and may impact the judicialization of healthcare"},"content":{"rendered":"<div data-elementor-type=\"wp-post\" data-elementor-id=\"5097\" class=\"elementor elementor-5097\" data-elementor-post-type=\"post\">\n\t\t\t\t<div class=\"elementor-element elementor-element-eab69ea e-flex e-con-boxed e-con e-parent\" data-id=\"eab69ea\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-66df641 elementor-widget elementor-widget-text-editor\" data-id=\"66df641\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The Ministry of Health approved a comprehensive set of regulations intended to discipline the implementation of the Pharmaceutical Assistance Component in Oncology (AF-Onco).<\/span><\/p><p><span style=\"font-weight: 400;\">Created by GM\/MS Ordinance No. 8,477\/2025, this component is part of the National Policy for the Prevention and Control of Cancer (PNPCC), with the mission of qualifying the prevention, diagnosis, and provision of specialized treatments within the Unified Health System (SUS)\u00b9<\/span><span style=\"font-weight: 400;\">.<\/span><\/p><p><span style=\"font-weight: 400;\">The agreement between the Union, the States and the Municipalities sets out guidelines for the distribution of logistical competences, the sharing of high-cost doses and the governance of care data\u00b2<\/span><span style=\"font-weight: 400;\">.<\/span><\/p><p>\u00a0<\/p><h3><b>The main regulatory guidelines of the new governance of AF-Onco<\/b><\/h3><p><span style=\"font-weight: 400;\">The package of regulations issued by the Executive Secretariat of the Ministry of Health structures the flow of supply of high-cost oncology drugs under new premises\u00b3<\/span><span style=\"font-weight: 400;\">:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Dosing and dose optimization centers (GM Regulations No. 11.540 and No. 12.085\/2026):<\/b><span style=\"font-weight: 400;\"> They foresee the joint action of federal entities to implement centers that allow the fractionation and sharing of doses among patients from the same region, minimizing the disposal of leftovers and optimizing public spending.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Flow control and authorization (SAES\/MS Circular No. 4,329\/2026): <\/b><span style=\"font-weight: 400;\">regulates the administrative procedures for the request and authorization of therapies by accredited oncology services, reinforcing the traceability of dispensations.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Exclusive APAC Onco Platform (SAES\/MS Circular No. 4,331\/2026): <\/b><span style=\"font-weight: 400;\">it makes the integration of this tool into national information systems mandatory for the individualized monitoring of the administration of medicines.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Official list of medicines (Joint Order SCTIE\/SAES\/MS No. 2\/2026):<\/b><span style=\"font-weight: 400;\"> defines the standardized relationship of high-cost oncology therapies provided under the component.<\/span><\/li><\/ul><p>\u00a0<\/p><h3><b>The expected impact on litigation and the judicialization of health care<\/b><\/h3><p><span style=\"font-weight: 400;\">The reorganization of the AF-Onco flow has a direct relationship with the mitigation of judicial litigation in public health.<\/span><\/p><p><span style=\"font-weight: 400;\">According to consolidated data from the National Council of Justice (CNJ), Brazil ended 2025 with more than 895 thousand ongoing cases in the health sector, approximately 495 thousand of which are related to the SUS, with a significant predominance of requests for oncological medications\u2074<\/span><span style=\"font-weight: 400;\">.<\/span><\/p><p><span style=\"font-weight: 400;\">In this scenario, the expectation of the Pharmaceutical Assistance Coordination Office of the State of S\u00e3o Paulo (CAF\/SP) is for a gradual reduction in judicialization as access to oncology drugs and treatments becomes more structured through more clear protocols. As highlighted by the CAF\/SP, the AF-Onco contributes to this by establishing more defined rules, distributing responsibilities among the entities, and reducing ambiguities that lead patients to the courts due to administrative failures, rather than a lack of supply.<\/span><\/p><p>\u00a0<\/p><h3><b>Reactions from the pharmaceutical industry and suppliers<\/b><\/h3><p><span style=\"font-weight: 400;\">For laboratories and distributors of oncological technologies, the structuring of the AF-Onco initiative inaugurates a more demanding dynamic of compliance and supply chain management:<\/span><\/p><ul><li style=\"font-weight: 400;\" aria-level=\"1\"><b>End-to-end traceability:<\/b><span style=\"font-weight: 400;\"> Nominal tracking through the digital platform will require greater rigor in the reconciliation of stocks and batches delivered.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Contracts and supply models: <\/b><span style=\"font-weight: 400;\">The creation of regional dilution centers and the direct delivery to federal hospitals and institutions such as INCA require logistical and operational adjustments in public contracts.<\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><b>Predictability of demand: <\/b><span style=\"font-weight: 400;\">The unified planning among the federal entities tends to provide greater predictability for public purchases of innovative therapies.<br \/><br \/><\/span><\/li><\/ul><p><span style=\"font-weight: 400;\">The careful monitoring of these regulations is essential to anticipate impacts on pricing, existing contracts, and the processes of incorporating technological innovations into the SUS.<\/span><\/p><p>\u00a0<\/p><h3><b>Strategic Questions about AF-Onco<\/b><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-fa82093 e-flex e-con-boxed e-con e-parent\" data-id=\"fa82093\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-3839c2d elementor-widget elementor-widget-n-accordion\" data-id=\"3839c2d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;default_state&quot;:&quot;expanded&quot;,&quot;max_items_expended&quot;:&quot;one&quot;,&quot;n_accordion_animation_duration&quot;:{&quot;unit&quot;:&quot;ms&quot;,&quot;size&quot;:400,&quot;sizes&quot;:[]}}\" data-widget_type=\"nested-accordion.default\">\n\t\t\t\t\t\t\t<div class=\"e-n-accordion\" aria-label=\"Accordion. Open links with Enter or Space, close with Escape, and navigate with Arrow Keys\">\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-5890\" class=\"e-n-accordion-item\" open>\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"1\" tabindex=\"0\" aria-expanded=\"true\" aria-controls=\"e-n-accordion-item-5890\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What is the role of the dilution units provided for in the AF-Onco? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5890\" class=\"elementor-element elementor-element-8988488 e-con-full e-flex e-con e-child\" data-id=\"8988488\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5890\" class=\"elementor-element elementor-element-0b840f4 e-flex e-con-boxed e-con e-child\" data-id=\"0b840f4\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-7bd9926 elementor-widget elementor-widget-text-editor\" data-id=\"7bd9926\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The central units enable the technical fractionation and the sharing of doses of high-cost oncological drugs among patients from the same locality, avoiding the waste of residual volumes in vials.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-5891\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"2\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-5891\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> In what way does the APAC Onco platform modify the routine of providers? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5891\" class=\"elementor-element elementor-element-bdfc9fe e-con-full e-flex e-con e-child\" data-id=\"bdfc9fe\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5891\" class=\"elementor-element elementor-element-2a79206 e-flex e-con-boxed e-con e-child\" data-id=\"2a79206\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ea0d902 elementor-widget elementor-widget-text-editor\" data-id=\"ea0d902\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">The tool makes the centralized digital recording of each request, authorization, and treatment dispensation mandatory, creating a unified national basis for the traceability of oncological care.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t\t<details id=\"e-n-accordion-item-5892\" class=\"e-n-accordion-item\" >\n\t\t\t\t<summary class=\"e-n-accordion-item-title\" data-accordion-index=\"3\" tabindex=\"-1\" aria-expanded=\"false\" aria-controls=\"e-n-accordion-item-5892\" >\n\t\t\t\t\t<span class='e-n-accordion-item-title-header'><div class=\"e-n-accordion-item-title-text\"> What impact does the new model have on public procurement processes? <\/div><\/span>\n\t\t\t\t\t\t\t<span class='e-n-accordion-item-title-icon'>\n\t\t\t<span class='e-opened' ><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-minus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h384c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t\t<span class='e-closed'><svg aria-hidden=\"true\" class=\"e-font-icon-svg e-fas-plus\" viewbox=\"0 0 448 512\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M416 208H272V64c0-17.67-14.33-32-32-32h-32c-17.67 0-32 14.33-32 32v144H32c-17.67 0-32 14.33-32 32v32c0 17.67 14.33 32 32 32h144v144c0 17.67 14.33 32 32 32h32c17.67 0 32-14.33 32-32V304h144c17.67 0 32-14.33 32-32v-32c0-17.67-14.33-32-32-32z\"><\/path><\/svg><\/span>\n\t\t<\/span>\n\n\t\t\t\t\t\t<\/summary>\n\t\t\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5892\" class=\"elementor-element elementor-element-6cf7a54 e-con-full e-flex e-con e-child\" data-id=\"6cf7a54\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t<div role=\"region\" aria-labelledby=\"e-n-accordion-item-5892\" class=\"elementor-element elementor-element-7695ef5 e-flex e-con-boxed e-con e-child\" data-id=\"7695ef5\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-dc17d2f elementor-widget elementor-widget-text-editor\" data-id=\"dc17d2f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<p><span style=\"font-weight: 400;\">By unifying competing responsibilities and standardizing the list of medicines, the system enables more direct logistical flows and centralized purchases with greater predictability of consumption.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/details>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-f6a59a7 e-flex e-con-boxed e-con e-parent\" data-id=\"f6a59a7\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-c61142c elementor-widget elementor-widget-text-editor\" data-id=\"c61142c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t\t\t\t\t\t<h3><b>Life Sciences and Healthcare<\/b><\/h3><p><span style=\"font-weight: 400;\">The Life Sciences and Healthcare practice of <\/span><b>Fialdini Einsfeld Advogados (FEADV) <\/b><span style=\"font-weight: 400;\">provides comprehensive legal support to pharmaceutical industries and healthcare institutions in the monitoring of public policies, technological integration processes, and regulatory compliance within the SUS. Our team acts proactively to mitigate contractual risks and discuss issues related to the judicialization of healthcare.<\/span><\/p><p>\u00a0<\/p><h4><b>References<\/b><\/h4><ol><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.in.gov.br\/en\/web\/dou\/-\/portaria-gm\/ms-n-8.477-de-20-de-outubro-de-2025-664002839\"><span style=\"font-weight: 400;\">BRAZIL. Ministry of Health. GM\/MS Ordinance No. 8,477 of October 20, 2025. Establishes the Pharmaceutical Assistance Component in Oncology (AF-Onco)<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/www.gov.br\/saude\/pt-br\/assuntos\/noticias-ms\/2026\/setembro\/sus-regulamenta-componente-da-assistencia-farmaceutica-em-oncologia\"><span style=\"font-weight: 400;\">BOLDRINI, Tatiany V. SUS regulates a component of pharmaceutical assistance in oncology. Ministry of Health, September 9, 2026<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/futurodasaude.com.br\/af-onco-novas-portarias-pactuadas\/\"><span style=\"font-weight: 400;\">KROLL, Rebeca. Ministry of Health agrees on new regulations to operationalize AF-Onco. Futuro da Sa\u00fade, June 25, 2026<\/span><\/a><\/span><\/li><li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"text-decoration: underline;\"><a href=\"https:\/\/futurodasaude.com.br\/af-onco-judicializacao-decisoes-sus\/\"><span style=\"font-weight: 400;\">WEISE, Ang\u00e9lica. With AF-Onco, judicialization becomes a criterion to guide decisions in the SUS. Futuro da Sa\u00fade, 22 April 2026<\/span><\/a><\/span><\/li><\/ol>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"<p>The new regulations of the Ministry of Health for the AF-Onco seek to standardize logistical flows and reduce the significant judicialization of oncological therapies.<\/p>","protected":false},"author":12,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[32],"tags":[36,55,56],"ppma_author":[33,28],"class_list":["post-5097","post","type-post","status-publish","format-standard","hentry","category-life-sciences-e-healthcare","tag-direito-sanitario","tag-judicializacao-da-saude","tag-sistema-unico-de-saude"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade - Fialdini Einsfeld Advogados<\/title>\n<meta name=\"description\" content=\"Conhe\u00e7a as novas portarias do Minist\u00e9rio da Sa\u00fade para o AF-Onco e seus reflexos na distribui\u00e7\u00e3o de rem\u00e9dios oncol\u00f3gicos e na judicializa\u00e7\u00e3o da sa\u00fade.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/feadv.com.br\/en\/new-regulations-on-oncology-reorganize-access-to-oncological-drugs-in-the-eu-and-may-impact-the-judicialization-of-healthcare\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade - Fialdini Einsfeld Advogados\" \/>\n<meta property=\"og:description\" content=\"Conhe\u00e7a as novas portarias do Minist\u00e9rio da Sa\u00fade para o AF-Onco e seus reflexos na distribui\u00e7\u00e3o de rem\u00e9dios oncol\u00f3gicos e na judicializa\u00e7\u00e3o da sa\u00fade.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/feadv.com.br\/en\/new-regulations-on-oncology-reorganize-access-to-oncological-drugs-in-the-eu-and-may-impact-the-judicialization-of-healthcare\/\" \/>\n<meta property=\"og:site_name\" content=\"Fialdini Einsfeld Advogados\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-08T14:00:02+00:00\" \/>\n<meta name=\"author\" content=\"Giulia Brumatti, Vict\u00f3ria Pereira\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Giulia Brumatti\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/\"},\"author\":{\"name\":\"Giulia Brumatti\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#\\\/schema\\\/person\\\/9599a63e5edfe1d04d8c2103baf85211\"},\"headline\":\"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade\",\"datePublished\":\"2026-10-08T14:00:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/\"},\"wordCount\":1016,\"publisher\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#organization\"},\"keywords\":[\"Direito Sanit\u00e1rio\",\"Judicializa\u00e7\u00e3o da Sa\u00fade\",\"Sistema \u00danico de Sa\u00fade\"],\"articleSection\":[\"Life Sciences e Healthcare\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/\",\"url\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/\",\"name\":\"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade - Fialdini Einsfeld Advogados\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#website\"},\"datePublished\":\"2026-10-08T14:00:02+00:00\",\"description\":\"Conhe\u00e7a as novas portarias do Minist\u00e9rio da Sa\u00fade para o AF-Onco e seus reflexos na distribui\u00e7\u00e3o de rem\u00e9dios oncol\u00f3gicos e na judicializa\u00e7\u00e3o da sa\u00fade.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/feadv.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#website\",\"url\":\"https:\\\/\\\/feadv.com.br\\\/\",\"name\":\"Fialdini Einsfeld Advogados\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/feadv.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#organization\",\"name\":\"Fialdini Einsfeld Advogados\",\"url\":\"https:\\\/\\\/feadv.com.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/feadv.com.br\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/FEADV_logo_completo_azul_marinho_RGB_.svg\",\"contentUrl\":\"https:\\\/\\\/feadv.com.br\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/FEADV_logo_completo_azul_marinho_RGB_.svg\",\"width\":1099,\"height\":619,\"caption\":\"Fialdini Einsfeld Advogados\"},\"image\":{\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/feadv.com.br\\\/#\\\/schema\\\/person\\\/9599a63e5edfe1d04d8c2103baf85211\",\"name\":\"Giulia Brumatti\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g81192319a4f71860b1ee85eea0ffddce\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g\",\"caption\":\"Giulia Brumatti\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AF-Onco: new regulations reorganize access to oncological drugs in the SUS and may impact the judicialization of healthcare - Fialdini Einsfeld Advogados","description":"Learn about the new regulations issued by the Ministry of Health for the AF-Onco and their implications on the distribution of oncological medications and the judicialization of healthcare.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/feadv.com.br\/en\/new-regulations-on-oncology-reorganize-access-to-oncological-drugs-in-the-eu-and-may-impact-the-judicialization-of-healthcare\/","og_locale":"en_US","og_type":"article","og_title":"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade - Fialdini Einsfeld Advogados","og_description":"Conhe\u00e7a as novas portarias do Minist\u00e9rio da Sa\u00fade para o AF-Onco e seus reflexos na distribui\u00e7\u00e3o de rem\u00e9dios oncol\u00f3gicos e na judicializa\u00e7\u00e3o da sa\u00fade.","og_url":"https:\/\/feadv.com.br\/en\/new-regulations-on-oncology-reorganize-access-to-oncological-drugs-in-the-eu-and-may-impact-the-judicialization-of-healthcare\/","og_site_name":"Fialdini Einsfeld Advogados","article_published_time":"2026-10-08T14:00:02+00:00","author":"Giulia Brumatti, Vict\u00f3ria Pereira","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Giulia Brumatti","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/#article","isPartOf":{"@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/"},"author":{"name":"Giulia Brumatti","@id":"https:\/\/feadv.com.br\/#\/schema\/person\/9599a63e5edfe1d04d8c2103baf85211"},"headline":"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade","datePublished":"2026-10-08T14:00:02+00:00","mainEntityOfPage":{"@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/"},"wordCount":1016,"publisher":{"@id":"https:\/\/feadv.com.br\/#organization"},"keywords":["Direito Sanit\u00e1rio","Judicializa\u00e7\u00e3o da Sa\u00fade","Sistema \u00danico de Sa\u00fade"],"articleSection":["Life Sciences e Healthcare"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/","url":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/","name":"AF-Onco: new regulations reorganize access to oncological drugs in the SUS and may impact the judicialization of healthcare - Fialdini Einsfeld Advogados","isPartOf":{"@id":"https:\/\/feadv.com.br\/#website"},"datePublished":"2026-10-08T14:00:02+00:00","description":"Learn about the new regulations issued by the Ministry of Health for the AF-Onco and their implications on the distribution of oncological medications and the judicialization of healthcare.","breadcrumb":{"@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/feadv.com.br\/af-onco-nova-regulamentacao-reorganiza-o-acesso-a-medicamentos-oncologicos-no-sus-e-pode-impactar-a-judicializacao-da-saude\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/feadv.com.br\/"},{"@type":"ListItem","position":2,"name":"AF-Onco: nova regulamenta\u00e7\u00e3o reorganiza o acesso a medicamentos oncol\u00f3gicos no SUS e pode impactar a judicializa\u00e7\u00e3o da sa\u00fade"}]},{"@type":"WebSite","@id":"https:\/\/feadv.com.br\/#website","url":"https:\/\/feadv.com.br\/","name":"Fialdini Einsfeld Lawyers","description":"","publisher":{"@id":"https:\/\/feadv.com.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/feadv.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/feadv.com.br\/#organization","name":"Fialdini Einsfeld Lawyers","url":"https:\/\/feadv.com.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/feadv.com.br\/#\/schema\/logo\/image\/","url":"https:\/\/feadv.com.br\/wp-content\/uploads\/2026\/08\/FEADV_logo_completo_azul_marinho_RGB_.svg","contentUrl":"https:\/\/feadv.com.br\/wp-content\/uploads\/2026\/08\/FEADV_logo_completo_azul_marinho_RGB_.svg","width":1099,"height":619,"caption":"Fialdini Einsfeld Advogados"},"image":{"@id":"https:\/\/feadv.com.br\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/feadv.com.br\/#\/schema\/person\/9599a63e5edfe1d04d8c2103baf85211","name":"Giulia Brumatti","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g81192319a4f71860b1ee85eea0ffddce","url":"https:\/\/secure.gravatar.com\/avatar\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g","caption":"Giulia Brumatti"}}]}},"authors":[{"term_id":33,"user_id":12,"is_guest":0,"slug":"giulia-brumatti","display_name":"Giulia Brumatti","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/8d3011a2028dcf63794d46d333bd1f38fd5ac290e81d9f4933efb23cc1f0e7be?s=96&d=mm&r=g","author_category":"6","first_name":"Giulia","last_name":"Brumatti","user_url":"","job_title":"","description":""},{"term_id":28,"user_id":10,"is_guest":0,"slug":"victoria-pereira","display_name":"Vict\u00f3ria Pereira","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/72b3231a7b948c934b89d5348a9d9b71fcb8e03c8e3cd5420355e051b20ac2df?s=96&d=mm&r=g","author_category":"6","first_name":"Vict\u00f3ria","last_name":"Pereira","user_url":"","job_title":"","description":""}],"_links":{"self":[{"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/posts\/5097","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/comments?post=5097"}],"version-history":[{"count":6,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/posts\/5097\/revisions"}],"predecessor-version":[{"id":5103,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/posts\/5097\/revisions\/5103"}],"wp:attachment":[{"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/media?parent=5097"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/categories?post=5097"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/tags?post=5097"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/feadv.com.br\/en\/wp-json\/wp\/v2\/ppma_author?post=5097"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}